JP2024510503A5 - - Google Patents
Info
- Publication number
- JP2024510503A5 JP2024510503A5 JP2023557352A JP2023557352A JP2024510503A5 JP 2024510503 A5 JP2024510503 A5 JP 2024510503A5 JP 2023557352 A JP2023557352 A JP 2023557352A JP 2023557352 A JP2023557352 A JP 2023557352A JP 2024510503 A5 JP2024510503 A5 JP 2024510503A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- sulfur
- nitrogen
- oxygen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163162477P | 2021-03-17 | 2021-03-17 | |
| US63/162,477 | 2021-03-17 | ||
| PCT/US2022/020479 WO2022197756A1 (en) | 2021-03-17 | 2022-03-16 | Plasma kallikrein inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024510503A JP2024510503A (ja) | 2024-03-07 |
| JP2024510503A5 true JP2024510503A5 (enExample) | 2025-03-24 |
Family
ID=81327137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023557352A Pending JP2024510503A (ja) | 2021-03-17 | 2022-03-16 | 血漿カリクレイン阻害剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240382482A1 (enExample) |
| EP (1) | EP4308228A1 (enExample) |
| JP (1) | JP2024510503A (enExample) |
| CN (1) | CN117396474A (enExample) |
| WO (1) | WO2022197756A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112135825A (zh) | 2018-03-13 | 2020-12-25 | 夏尔人类遗传性治疗公司 | 血浆激肽释放酶抑制剂及其用途 |
| CN114728962B (zh) | 2019-09-18 | 2025-09-19 | 武田药品工业有限公司 | 血浆激肽释放酶抑制剂及其用途 |
| WO2021055589A1 (en) | 2019-09-18 | 2021-03-25 | Shire Human Genetic Therapies, Inc. | Heteroaryl plasma kallikrein inhibitors |
| WO2022197755A1 (en) * | 2021-03-17 | 2022-09-22 | Shire Human Genetic Therapies, Inc. | Imidazopyridinyl inhibitors of plasma kallikrein |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| DK0495421T3 (da) | 1991-01-15 | 1996-12-09 | Alcon Lab Inc | Anvendelse af carragenaner i topiske ophthalmiske sammensætninger |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| US6887870B1 (en) * | 1999-10-12 | 2005-05-03 | Bristol-Myers Squibb Company | Heterocyclic sodium/proton exchange inhibitors and method |
| AU2008309517B2 (en) * | 2007-10-12 | 2013-03-14 | Astrazeneca Ab | Inhibitors of protein kinases |
| US8927559B2 (en) * | 2010-10-11 | 2015-01-06 | Merck Sharp & Dohme Corp. | Quinazolinone-type compounds as CRTH2 antagonists |
| US9624170B2 (en) * | 2013-12-26 | 2017-04-18 | Takeda Pharmaceutical Company Limited | 4-(piperrazin-1-yl)-pyrrolidin-2-one compounds as monoacylglycerol lipase (MAGL) inhibitors |
| CN106794181A (zh) * | 2014-06-04 | 2017-05-31 | 托马斯·黑勒戴药物研究基金会 | 用于治疗炎性和自身免疫性病况的mth1抑制剂 |
| WO2016010108A1 (ja) * | 2014-07-18 | 2016-01-21 | 塩野義製薬株式会社 | 含窒素複素環誘導体およびそれらを含有する医薬組成物 |
| US9815853B2 (en) | 2015-06-12 | 2017-11-14 | Global Blood Therapeutics, Inc. | Bridged bicyclic kallikrein inhibitors |
| ME03794B (me) | 2016-05-31 | 2021-04-20 | Kalvista Pharmaceuticals Ltd | Derivati pirazola kao inhibitori kalikreina plazme |
| CN112135825A (zh) * | 2018-03-13 | 2020-12-25 | 夏尔人类遗传性治疗公司 | 血浆激肽释放酶抑制剂及其用途 |
-
2022
- 2022-03-16 US US18/550,571 patent/US20240382482A1/en active Pending
- 2022-03-16 JP JP2023557352A patent/JP2024510503A/ja active Pending
- 2022-03-16 WO PCT/US2022/020479 patent/WO2022197756A1/en not_active Ceased
- 2022-03-16 CN CN202280033916.XA patent/CN117396474A/zh active Pending
- 2022-03-16 EP EP22714694.1A patent/EP4308228A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024516073A5 (enExample) | ||
| JP2022548696A5 (enExample) | ||
| JP5387699B2 (ja) | Ｅｐ４アゴニストを有効成分とする骨量低下疾患の治療剤 | |
| ES2892550T3 (es) | Compuestos útiles como inmunomoduladores | |
| JP2022537158A5 (enExample) | ||
| JP2019013227A5 (enExample) | ||
| JP2024510502A5 (enExample) | ||
| JP2024545233A5 (enExample) | ||
| JP2024510504A5 (enExample) | ||
| JP2024512497A5 (enExample) | ||
| JP2020528937A5 (enExample) | ||
| AU2004249639B2 (en) | Tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them | |
| MXPA04008596A (es) | Compuestos derivados de 8-azaprostaglandina y farmacos que contienen los compuestos como ingrediente activo. | |
| JP5265518B2 (ja) | アルテミシニン誘導体の二量体、この調製およびこの治療上の使用 | |
| JP2012530703A5 (enExample) | ||
| KR20040026678A (ko) | 택솔 인핸서 화합물 | |
| ES2849998T3 (es) | Compuestos heterocíclicos y su uso | |
| JP2023506410A5 (enExample) | ||
| JP2023515888A5 (enExample) | ||
| WO2000004026A1 (en) | Trioxane derivatives | |
| CN107141410A (zh) | 聚合物缀合的MetAP2抑制剂及其应用的治疗方法 | |
| ES2866104T3 (es) | Procedimiento para la preparación de depsipéptidos cíclicos | |
| TW200913986A (en) | Hydroxy sulfonate of quinone compounds and their uses | |
| US20030176486A1 (en) | Sulfonic acid derivatives of hydroxamic acids and their use as medicinal products | |
| BRPI0706283A2 (pt) | composto, composição farmacêutica e métodos de preparação do composto e de tratamento de condição pré-cancerìgena ou cáncer em mamìfero |